The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Journal of Psychiatric Research

Volumn 61, Issue , 2015, Pages 1-12

  Saveanu, Radu ^a   Etkin, Amit ^b,c   Duchemin, Anne Marie ^a   Goldstein Piekarski, Andrea ^b,c   Gyurak, Anett ^b,c   Debattista, Charles ^b   Schatzberg, Alan F ^b   Sood, Satish ^d   Day, Claire V A ^e,f,g   Palmer, Donna M ^e,f,g   Rekshan, William R ^f,g   Gordon, Evian ^f,g   Rush, A John ^h   Williams, Leanne M ^b,c,e  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Shanti Clinical Trials   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Brain Resource Ltd   (Australia)

^g Brain Resource International Database   (United States)

^h DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Escitalopram; International practical trial; Major depressive disorder; Response and remission; Sertraline; Venlafaxine XR

Indexed keywords

ESCITALOPRAM; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; FUNCTIONAL STATUS; GENERALIZED ANXIETY DISORDER; HAMILTON DEPRESSION RATING SCALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SOCIAL PHOBIA; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ANXIETY; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS; MIDDLE AGED; PROGNOSIS; PSYCHOLOGY; RANDOMIZATION; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANXIETY; COHORT STUDIES; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOM ALLOCATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921538482     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.12.018     Document Type: Article

References (63)

1. Alexopoulos G.S., Kelly R.E. Research advances in geriatric depression. World Psychiatry 2009, 8(3):140-149.
2. American Psychiatric Association Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993, 150(4 Suppl.):1-26.
3. Baghai T.C., Blier P., Baldwin D.S., Bauer M., Goodwin G.M., Fountoulakis K.N., et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2011, 261(Suppl.3):S207-S245.
4. Bauer M., Tharmanathan P., Volz H.P., Moeller H.J., Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009, 259:172-185.
5. Bileski R.J., Ventura D., Chang C.C. Adouble-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. JClin Psychiatry 2004, 65:1190-1196.
6. Cleary P., Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977, 1:115-120.
7. Depression Guideline Panel Clinical practice guideline. Number 5. Depression in primary care. Treatment of major depression 1993, vol. 2. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville, MD, (AHCPR Publication No. 93-0551).
8. Diener E., Emmons R.A., Larsen R.J., Griffin S. The satisfaction with life scale. JPers Assess 1985, 49:71-75.
9. Eckert L., Falissard B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine-XR. Current Medical Research and Opinion 2006, 22(11):2313-2321.
10. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19:179-200.
11. Fava M., Uebelacker L.A., Alpert J.E., Nierenberg A.A., Pava J.A., Rosenbaum J.F. Major depressive subtypes and treatment response. Biol Psychiatry 1997, 42:568-576.
12. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008, 165:342-351.
13. Fitzmaurice G.M. Methods for handling dropouts in longitudinal clinical trials. Stat Neerl 2003, 57(1):75-99. 10.1111/1467-9574.00222.
14. Flint A.J.P., Rifat S.L. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry 1997, 5:107-115.
15. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA 2010, 303(1):47-53.
16. Frank E., Prien R., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991, 48:851-855.
17. Frank E., Karp J.F., Rush A.J. Efficacy of treatments for major depression. Psychopharmacol Bull 1993, 29:457-475.
18. Gartlehner G., Gaynes B.N., Hansen R.A., Thieda P., DeVeaugh-Geiss A., Krebs E.E., et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149:734-750. [Review].
19. Gaynes B.N., Rush A.J., Trivedi M., Wisniewski S.R., Balasubramani G.K., Spencer D.C., et al. Adirect comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 2005, 27:87-96.
20. Gibbons R.D., Hur K., Brown C.H., Davis J.M., Mann J.J. Who benefits from antidepressants?. Arch Gen Psychiatry 2012, 69(6):572-579.
21. Gill J.M., Klinkman M.S., Chen Y.X. Antidepressant medication use for primary care patients with and without medical comorbidities: a national Electronic Health Record (HER) Network study. JAm Board Fam Med 2010, 23:499-508.
22. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149:1148-1156.
23. Gross J.J., John O.P. Individual differences in two emotion regulation processes: implications for affect, relationships and well-being. JPers Soc Psychol 2003, 85:348-362.
24. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-61.
25. Howland R.H., Wilson M.G., Kornstein S.G., Clayton A.H., Trivedi M.H., Wohlreich M.M., et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008, 20:209-218.
26. Howland R.H., Rush A.J., Wisniewski S.R., Trivedi M.H., Warden D., Fava M., et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 2009, 99:248-260.
27. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010, 167:748-751.
28. Joffe R.T., Bagby R.M., Levitt A. Anxious and nonanxious depression. Am J Psychiatry 1993, 150:1257-1258.
29. Kennedy S.H. Areview of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord 2013, 15. PCC 12r01420.
30. Kennedy S.H., Andersen H.F., Thase M.E. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009, 25:161-175.
31. Kim J.M., Kim S.W., Stewart R., Kim S.Y., Yoon J.S., Jung S.W., et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol 2011 Jan, 26(1):41-50.
32. Kobak K.A., Williams J.B., Engelhardt N. Acomparison of face-to-face and remote assessment of inter-rater reliability on the Hamilton Depression Rating Scale via videoconferencing. Psychiatry Res 2008, 158(1):99-103.
33. Kuk A.Y., Li J., Rush A.J. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. JClin Psychiatry 2010, 71:1502-1508.
34. Lovibond P.F. Long-term stability of depression, anxiety, and stress syndromes. JAbnorm Psychol 1998, 107(3):520-526.
35. Mark T.L., Levit K.R., Buck J.A. Psychotropic drug prescriptions by medical specialty. Psychiatr Serv 2009, 60(9):1167.
36. McGrath P.J., Khan A.Y., Trivedi M.H., Stewart J.W., Morris D.W., Wisniewski S.R., et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR-D report. JClin Psychiatry 2008, 69:1847-1855.
37. McGrath C.L., Kelley M.E., Holtzheimer P.E., Dunlop B.W., Craighead W.E., Franco A.R., et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013, 70(8):821-829.
38. Morishita S., Kinoshita T. Predictors of response to sertaline in patients with major depression. Human Psychopharmacology 2008, 23(8):647-651.
39. Nelson J.C. Anxious depression and response to treatment. Am J Psychiatry 2008, 165:297-299.
40. Papakostas G.I., Fava M. Predictors, moderators and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci 2008, 10:439-451.
41. Rosenbaum J.F., Fava M., Nierenberg A.A., Sachs G.S. Treatment-resistant mood disorders. Treatments of psychiatric disorders 2001, 1307-1384. American Psychiatric Press, Inc, Washington, DC. 3rd ed. G.O. Gabbard (Ed.).
42. Rush A.J., Rose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005, 21:26-32.
43. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54:573-583.
44. Rush A.J., Zimmerman M., Wisniewski S.R., Fava M., Hollon S.D., Warden D., et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. JAffect Disord 2005, 87(1):43-55.
45. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
46. Rush A.J., Wisniewski S.R., Warden D., Luther J.F., Davis L.L., Fava M., et al. Selecting among second-step antidepressants medication monotherapies: predictive values of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008, 8:870-880.
47. Rush A.J., Warden D., Wisniewski S.R., Fava M., Trivedi M.H., Gaynes B.N., et al. STAR*D: revising conventional wisdom. CNS Drugs 2009, 23:627-647.
48. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medication to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
49. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. JClin Psychiatry 1998, 59(Suppl.20):22-33.
50. Sicras-Mainar A., Maurino J., Cordero L., Blanca-Tamayo M., Navarro-Artieda R. Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. Ann Gen Psychiatry 2012 Aug 3, 11(1):22.
51. Silverstein B., Patel P. Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR-D study. Psychiatry Res 2011, 187(1-2):121-124. Epub 2011 Jan 8.
52. Thase M.E., Rush A.J. Treatment-resistant depression. Psychopharmacology: fourth generation of progress 1995, 1081-1097. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
53. Thiels C., Linden M., Grieger F., Leonard J. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 2005, 20:1-7.
54. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., Biggs M.M., Suppes T., et al. The Inventory of Depressive Symptomatology, Clinician rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004, 34:73-82.
55. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
56. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382(9904):1575-1586.
57. Williams L.M., Rush A.J., Koslow S.H., Wisniewski S.R., Cooper N.J., Nemeroff C.B., et al. International Study to Predict Optimized Treatment in Depression (iSPOT-D), randomized clinical trial: rationale and protocol. Trials 2011, 12:4.
58. Wisniewski S.R., Rush A.J., Balasubramani G.K., Trivedi M.H., Nierenberg A.A., STAR*D Investigators Self-rated global measure of the frequency, intensity, and burden of side effects. JPsychiatr Pract 2006, 12(2):71-79.
59. World Health Organization Mental health: mental health atlas 2011 2012, [Page on the Internet], World Health Organization, Switzerland, [cited June 28, 2011] Available from:. http://www.who.int/mental_health/publications/mental_health_atlas_2011/en/index.html.
60. World Health Organization Group Development of the World Health Organization WHOQoL-BREF quality of life assessment. Psychol Med 1998, 28:551-558.
61. Yates W.R., Mitchell J., Rush A.J., Trivedi M., Wisniewski S., Warden D., et al. Clinical features of depressed outpatients with and without general medical conditions in STAR*D. Gen Hosp Psychiatry 2004, 26(6):421-429.
62. Yeung A.S., Jing Y., Brenneman S.K., Chang T.E., Baer L., Hebden T., et al. Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. Depress Anxiety 2012 Oct, 29(10):865-873.
63. Young E.A. Sex differences in response to citalopram: a STAR-D report. JPsychiatr Res 2009, 43:503-511.